http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yasumoto Matsui (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Sarcopenia affects conservative treatment of osteoporotic vertebral fracture
Hiroki Iida,Yoshihito Sakai,Tsuyoshi Watanabe,Hiroki Matsui,Marie Takemura,Yasumoto Matsui,Yasumoto Matsui,Tetsuro Hida,Kenyu Ito,Sadayuki Ito 대한골다공증학회 2018 Osteoporosis and Sarcopenia Vol.4 No.3
Objectives: Sarcopenia and osteoporosis affects activities of daily living and quality of elderly people. However, little is known about its impact on elderly locomotor diseases, such as osteoporotic vertebral fracture (OVF). There is no report investigating the influence of both sarcopenia and osteoporosis on outcomes of OVF. This study aimed to evaluate the clinical outcomes of OVF in elderly patients from sarcopenic perspectives. Methods: This prospective study was conducted with 396 patients, aged 65 years or more, hospitalized for the treatment of OVF (mean age, 81.9 ± 7.1 years; 111 males, 285 females). The primary outcome was the Japanese Orthopaedic Association (JOA) score for lumbar disease (at first visit, hospital discharge, and 1 year after treatment) and Barthel index (at the same time and before hospitalization). The second outcome was living place after discharge. Susceptibility to sarcopenia and osteoporosis were evaluated and clinical results of conservative treatment were compared. Results: Sarcopenia significantly affected Barthel index at first visit and discharge. Sarcopenia patients had significantly higher rate for discharge to nursing home and living in nursing home after 1 year than patients without sarcopenia. Osteoporosis significantly affected the JOA score at the first visit and the Barthel index before hospitalization, at the first visit, discharge, and after 1 year. Osteoporosis did not affect the living place at discharge and after 1 year. Conclusions: Sarcopenia and osteoporosis affected outcomes of conservative treatment for OVF; moreover, sarcopenia affected the living place of OVF patients at discharge and after 1 year
-
Effect of alendronate on muscle mass: Investigation in patients with osteoporosis
Atsushi Harada,Sadayuki Ito,Yasumoto Matsui,Yoshihito Sakai,Marie Takemura,Haruhiko Tokuda,Tetsuro Hida,Hiroshi Shimokata 대한골다공증학회 2015 Osteoporosis and Sarcopenia Vol.1 No.1
Objectives: Many osteoporosis drugs reliably increase bone mass in the elderly; if these drugs also had a positive effect on muscle, their benefit would be even greater. We examined the effect of alendronate monotherapy on muscle mass in patients with osteoporosis. Methods: In this retrospective cohort, case-control study, patients from an osteoporosis database were divided into 2 groups: alendronate-treated patients (group A; n ¼ 199) and a control group receiving no drug treatment (group C; n ¼ 233). Appendicular skeletal muscle mass (ASM) and skeletal muscle mass index (SMI) measured by dual-energy X-ray absorptiometry were assessed at approximately 1 year. The change in muscle mass was compared between the groups. Results: At baseline, group A included more women and had lower height, weight, bone mineral content, and muscle mass than group C. A comparison of changes after 1 yeardadjusted for age, sex, observation period, body mass index and initial valuesdrevealed that the muscle mass in group A showed increases by 0.137 kg/m2 in SMI, 514 g in ASM, and 319 g in lower limb muscle mass (LLM). Group C showed no changes in muscle mass. A significant difference in the amount of change in ASM and LLM was found between the groups after adjustment: 2.5 times and 4.4 times higher, respectively, in groups A and C. However, the difference in SMI disappeared after adjustment. Conclusions: This is the first study to show that alendronate may have a positive effect not only on bone, but on muscle as well.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
